Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

al insights into the potential utility of RIT in intermediate grade NHL, a subtype where CRs are infrequent with rituximab therapy," noted Jack W. Singer, M.D., Chief Medical Officer of CTI.

The study results are reported in the current issue of CANCER at http://www3.interscience.wiley.com/journal/104532863/issue

Study Details

Between February 2005 and June 2006 26 eligible patients with previously untreated, indolent, nonfollicular NHL (10 marginal zone, 8 lymphocytoplasmic, and 8 small lymphocytic) were treated using a novel regimen that consisted of 6 cycles of fludarabine/mitoxantrone (FM) chemotherapy followed 6 to 10 weeks later by yttrium-90(90Y) ibritumomab tiuxetan (Zevalin(R)). After chemotherapy the overall response rate was 80.5% and included 50% CR and 30.5% PR. Of the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The FM treatment was well-tolerated; there were no treatment-related deaths. Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. Only 1 patient developed febrile neutropenia. Following Zevalin administration grade 3-4 thrombocytopenia occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors concluded "In this study we established the feasibility, tolerability and efficacy of sequential treatement with 6 cycles of FM chemotherapy followed by 90Y ibritumomab tiuxetan as front line therapy for patients with untreated, indolent, nonfollicular NHL. To our knowledge the data repr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Four novel genes that may,significantly increase the ... have been identified by researchers at Massachusetts General,Hospital ... November 7th issue,of American Journal of Human Genetics. ... (AGP) established three years ago to identify,the full ...
... FREMONT, Calif., Oct. 29 Vermillion, Inc.,(OTC Bulletin ... with Quest,Diagnostics to extend the Strategic Alliance Agreement ... enable the companies to continue,work on the development ... The OVA1 test is intended to identify women ...
Cached Medicine Technology:Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 2Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4
(Date:4/18/2014)... discovery that turns 160 years of neuroanatomy on its ... to be essential for the fast transmission of impulses ... ubiquitous as thought, according to a new work lead ... Institute (HSCI) and the University,s Department of Stem Cell ... of Harvard,s Department of Molecular and Cellular Biology. , ...
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Urges LCA-Vision Stockholders to Vote GOLDCINCINNATI, Feb. 27 ... Glass Lewis & Co., LLC, a leading independent research ... vote to retain the Company,s current Board of Directors ... of the current Directors and election of replacement Directors, ...
... United States Agency for International Development (USAID) is providing ... 15 and 16 in Columbia. Due to the ... extensive flooding in Tumaco municipality, Narino Department in Colombia, ... estimated 31,250 people.The money will be provided to humanitarian ...
... 27 Governor Edward G. Rendell ... nominations subject to Senate confirmation:State Board of Medicine ... Board of Examiners of Nursing Home Administrators , ... is committed to creating a first-rate public education ...
... But many people ignore the ,whisper, of trouble , , FRIDAY, ... having a stroke, you,d seek immediate medical attention. But what ... people who experience vague symptoms of a stroke suffer mental ... have found. , The implicit message? Don,t wait for ...
... 27 Dean Farms in New Castle, Lawrence County, ... resumed sales of raw milk on Feb. 26, Agriculture ... that has not been pasteurized. Pennsylvania farms selling raw ... milk laboratory tested due to the health risks associated ...
... track with boring tasks, study suggests, , , FRIDAY, Feb. ... paying attention when you doodle, but science says otherwise. ... subjects who doodled while listening to a recorded message had ... those who didn,t doodle. The findings were published in ...
Cached Medicine News:Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 4Health News:Even Mild Strokes Can Do Harm 2Health News:Even Mild Strokes Can Do Harm 3Health News:Correction: Lawrence County Raw Milk Dairy Tests Negative for Campylobacter; Raw Milk Sales Resumed 2Health News:Take Note: Doodling Can Help Memory 2
... of the outstanding features of our Neomax ... Molding Technology. , This manufacturing process allows ... controls the bunching and irritation in the ... wearer. , ,Colors available: Blue, ...
... be the world's most versatile functional knee ... support, or both, Flex is equipped for ... hinges control flexion and extension and its ... being heat-moldable to accommodate changes in leg ...
... Donut is a neoprene alternative, constructed ... polyester Lycra Fabric that allows for ... provides for patellar control. Ideal for ... or irritations. Click here to view ...
... The cool version of the TROM ... range-of-motion and locking capabilities as the full ... warmer climates. The ease of use and ... a variety of protocols following major ligament ...
Medicine Products: